Publication: 3125

Publication: 3125

A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: J Thorac Oncol vol 15 (1) 110-119

Year:: 2020
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 9

Parents:: 960
Children:: None

Program:: OGC
Primary Committee:: Respiratory
Sec. Committees:

Pharmas:: Neotropix, Inc
Grants:: U10CA180821, U10CA180882, U10CA180866, U10CA180790, U10CA180791, U10CA233196, U10CA233290, U10CA180820, UG1CA189952, U10CA180888

Corr. Author:
Authors:: Erin L. Schenk Sumithra J. Mandrekar Grace K. Dy Marie Christine Aubry Angelina D. Tan Shaker R. Dakhil Bradley A. Sachs Jorge J. Nieva Erin Bertino Christine Lee Hann Steven E. Schild Troy W. Wadsworth Alex A. Adjei Julian R. Molina

Networks:: CA011, KS055, LAPS-CO070, LAPS-MD017, LAPS-MN026, LAPS-NY158, OH008, WA030

Study: NCCTG-N0923
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Small cell lung cancer, virotherapy, NTX-010